HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
Saved in:
| Main Authors: | Devis Pascut, Muhammad Yogi Pratama, Claudio Tiribelli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2020-06-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/hep-2020-0010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01) -
Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01) -
Elimination of HCV replication machinery early after antiviral treatment with DAA monitored by multimodal microscopy
by: Castro Victoria, et al.
Published: (2024-01-01) -
Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status
by: Sylwia Osuch, et al.
Published: (2025-06-01) -
Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)